# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Diana, Princess of Wales (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML028-SYN-TD
- Date: 1990-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Castleford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review: binge and purge frequency, electrolytes, dental care, mood, and safety. **S**

## History of present illness

Ms. Spencer returns three months after her first visit. She has had sixteen CBT-E sessions and is now working with her therapist on her concerns about shape and weight and on binges that follow difficult days. She has had two episodes of binge eating with vomiting in the last four weeks, both after long working days. She eats three meals and two snacks on six or seven days a week. She saw a dentist three weeks ago: the erosion was confirmed, a fluoride varnish was applied, no new decay was found, and a review was set for six months. She takes fluoxetine 60 mg each morning and an over-the-counter folic acid tablet. She completed the mid-treatment EDE-Q with her therapist. Her mood is good and she has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Binge eating and vomiting | Two episodes in the last four weeks |
| CBT-E | Sixteen sessions; weekly |
| Regular eating | Three meals and two snacks on six or seven days a week |
| Dental examination | Done three weeks ago; fluoride varnish; review in six months |
| Mood | Good; PHQ-9 5; item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Gastrointestinal | Negative | Two episodes of vomiting in four weeks; no heartburn or abdominal pain |
| Ears, nose, mouth, and throat | Negative | Tooth sensitivity better since the varnish |
| Psychiatric | Negative | Mood good; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Fluoxetine 60 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 62 kg; BMI 19.6 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Chloride: 102 mmol/L; Bicarbonate (total CO2): 25 mmol/L; Creatinine: 0.79 mg/dL; eGFR: 104 mL/min/1.73 m²; Amylase: 88 U/L; PHQ-9: 5. All results are synthetic.

## Change since baseline

- Sodium: 137 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 3.1 mmol/L (low) at baseline, 4.1 mmol/L at this visit **S**
- Chloride: 94 mmol/L (low) at baseline, 102 mmol/L at this visit **S**
- Bicarbonate (total CO2): 32 mmol/L (high) at baseline, 25 mmol/L at this visit **S**
- Creatinine: 0.84 mg/dL at baseline, 0.79 mg/dL at this visit **S**
- eGFR: 97 mL/min/1.73 m² at baseline, 104 mL/min/1.73 m² at this visit **S**
- Amylase: 146 U/L (high) at baseline, 88 U/L at this visit **S**
- PHQ-9: 14 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 62.0 kg, BMI 19.6; lying blood pressure 108/68 and pulse 68, standing 108/70 and pulse 76 after three minutes |
| Head and neck | Parotid glands now barely enlarged; enamel erosion stable |
| Skin | Knuckle calluses gone |
| Psychiatric | Euthymic and engaged; organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bulimia nervosa, severe** (F50.23). Marked improvement: two episodes in four weeks, from about ten a week at intake, and an EDE-Q global score of 2.1, from 3.9. Potassium 4.1 mmol/L and bicarbonate 25 mmol/L; amylase back to normal at 88 U/L as the parotid swelling settles. The dental examination is done. **S**
   - Continue CBT-E weekly to the end of the 20 sessions, then a written relapse-prevention plan.
   - Continue fluoxetine 60 mg each morning.
   - Dental review in six months.
2. **Major depressive disorder, recurrent, moderate** (F33.1). PHQ-9 5, from 14. Safety reviewed: no thoughts of suicide or self-harm; the safety plan is current. **S**
   - PHQ-9 at the end-of-treatment visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Binge-eating and vomiting frequency (her self-monitoring record) | Every visit | Completed today | Two episodes in the last four weeks |
| Survey | Eating Disorder Examination Questionnaire (EDE-Q) global score | Baseline, mid-treatment, and end of treatment | Completed today | Global score 2.1 at mid-treatment, from 3.9 |
| Examination | Weight and BMI | Every visit, and weekly in CBT-E sessions | Completed today | 62.0 kg, BMI 19.6 |
| Examination | Lying and standing pulse and blood pressure | Every visit while purging continues | Completed today | Lying 108/68, pulse 68; standing 108/70, pulse 76 (rise 8) |
| Laboratory | Potassium, chloride, bicarbonate, and creatinine | Weekly until potassium is normal twice, then at each medical visit while purging continues | Completed today | Potassium 4.1 mmol/L off supplements; sodium 139, chloride 102, bicarbonate 25 mmol/L; creatinine 0.79 mg/dL, eGFR 104 |
| Laboratory | Amylase | Baseline with parotid enlargement; repeat as indicated | Completed today | 88 U/L, from 146 at intake |
| Laboratory | ECG with QTc | Baseline with purging or low potassium; after a QT-relevant medicine reaches its full dose while potassium has been low | Not indicated | QTc 441 ms on fluoxetine 60 mg with normal potassium; no further routine ECG unless symptoms, low potassium, or a new QT-relevant medicine |
| Examination | Parotid and dental examination; dental protection | Every visit; a dental examination soon after diagnosis and regular dental reviews while vomiting continues | Completed today | Dental examination done three weeks ago, about ten weeks after it was advised at intake; erosion stable, fluoride varnish, no new decay, review in six months. The delay is closed; no harm resulted |
| Medication safety | Fluoxetine dose, adherence, and side effects (nausea, sleep, agitation, sexual effects, suicidal thoughts) | At the start, one to two weeks after starting or a dose change, then every visit | Completed today | 60 mg; no side effects; no agitation or suicidal thoughts |
| Self-management | CBT-E attendance and progress | Up to 20 sessions over 20 weeks, twice weekly for the first four weeks | Completed today | Sixteen sessions; weekly |
| Self-management | Regular eating and dietitian review | Every visit | Completed today | Three meals and two snacks on six or seven days a week |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, then periodically | Completed today | PHQ-9 5, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current |

## Goal progress

- No binge eating or vomiting for at least four weeks by the end of 20 weeks of CBT-E. In progress; target 1990-07-13. **S**
- Potassium at least 3.5 mmol/L on two checks within four weeks. Outcome by 1990-03-16: Potassium 3.6 and 3.9 mmol/L; supplement stopped. **S**
- Regular eating (three meals and two or three snacks) on most days by three months. Outcome by 1990-05-11: Regular eating on six or seven days a week. **S**
- PHQ-9 score below 5 by the end of treatment. In progress; target 1990-07-13. **S**
- EDE-Q global score below 2.0 by the end of treatment. In progress; target 1990-07-13. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023), American Psychiatric Association (American Journal of Psychiatry 2023;180(2):167-171)
- Eating disorders: recognition and treatment (NICE guideline NG69) (2017, updated 2020), National Institute for Health and Care Excellence
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- CBT-E weekly to session 20. End-of-treatment review in about nine weeks with electrolytes, the EDE-Q, and the PHQ-9. **S**
- Next scheduled visit 1990-07-13: end-of-treatment review after 20 weeks of CBT-E: remission, relapse prevention, and continuing fluoxetine. **S**
